Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CDC25B | P30305 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | CDC25A | P30304 | 1/20 | 0.46 |
| ▸ | CDC25C | P30307 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.43 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20514279 | 1.00 | ALDH1A1 (0.50) | ALDH1A1HPGDCDC25BCYP1A2CYP2C9 | |
| SCHEMBL1433197 | 0.84 | ALDH1A1 (0.53) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL7437199 | 0.84 | ALDH1A1 (0.52) | ALDH1A1HPGDCYP1A2CYP2C9CYP2C19 | |
| SCHEMBL31360448 | 0.83 | KMT2A (0.52) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL15203285 | 0.83 | KMT2A (0.52) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL25156303 | 0.83 | KMT2A (0.52) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL10412730 | 0.83 | ALDH1A1 (0.51) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL11264265 | 0.82 | GAA (0.44) | ALDH1A1HPGDCYP1A2KMT2AKDM4E | |
| SCHEMBL28480579 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HPGDCDC25BCDC25ACDC25C | |
| SCHEMBL283096 | 0.81 | ALDH1A1 (0.50) | ALDH1A1HPGDCDC25BCDC25ACDC25C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3380970-B1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-01-04 | — | — | EP | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| EP-3655398-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | Phenex-FXR GmbH (DE) | 2020-05-27 | — | — | EP | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | PHENEX-FXR GMBH (DE) | 2020-04-30 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| CN-110914248-A | LXR modulators containing amines or (thio) amides | 菲尼克斯-FXR股份有限公司 | 2020-03-24 | — | — | CN | disclosed |
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | AMERICAN CYANAMID COMPANY (US) | 2002-10-10 | — | — | US | disclosed |
| US-6340691-B1 | TREATMENT OF ARTHRITIS, TUMOR METASTASIS, TISSUE ULCERATION, ABNORMAL WOUND HEALING, PERIODONTAL DISEASE, BONE DISEASE, DIABETES (INSULIN RESISTANCE) AND HIV INFECTION | AMERICAN CYANAMID COMPANY | 2002-01-22 | — | — | US | disclosed |
| US-5449682-A | Angiotensin II antagonists incorporating a substituted benzyl element | MERCK & CO., INC. (US) | 1995-09-12 | — | — | US | disclosed |
| EP-0623120-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1994-11-09 | — | — | EP | disclosed |
| US-5240938-A | Angiotensin II antagonists incorporating a substituted pyridoimidazolyl ring | MERCK & CO., INC. (US) | 1993-08-31 | — | — | US | disclosed |
| WO-1993014077-A1 | PIPERIDINEACETIC ACID DERIVATIVES AS INHIBITORS OF FIBRINOGEN-DEPENDENT BLOOD PLATELET AGGREGATION | GLAXO GROUP LIMITED (GB) | 1993-07-22 | — | — | WO | disclosed |
| WO-1991011999-A1 | ANGIOTENSIN II ANTAGONISTS INCORPORATING A SUBSTITUTED BENZYL ELEMENT | MERCK & CO., INC. (US) | 1991-08-22 | — | — | WO | disclosed |
| US-4203855-A | Phenoxide-halo carboxylic acid condensate additives for lubricants | THE LUBRIZOL CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-4128488-A | Overbased phenoxide-halo carboxylic acid condensate additives for lubricants | THE LUBRIZOL CORPORATION (US) | 1978-12-05 | — | — | US | disclosed |
| US-4061474-A | Phenoxide-halo carboxylic acid condensate additives for fuels | THE LUBRIZOL CORPORATION (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147342-A1 | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors | MMP12, MMP17, MMP14 | ALDH1A1 443/4885HPGD 296/4885CDC25B 1422/4885 |
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | ALDH1A1 2642/4885HPGD 4292/4885CDC25B 4507/4885 |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | ALDH1A1 2642/4885HPGD 4292/4885CDC25B 4507/4885 |
| US-20200131144-A1 | AMINE OR (THIO)AMIDE CONTAINING LXR MODULATORS | NR1H2, NR1H3, NR1H4 | ALDH1A1 2016/4885HPGD 1518/4885CDC25B 4385/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | ALDH1A1 2968/4885HPGD 4302/4885CDC25B 4545/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | ALDH1A1 2845/4885HPGD 4319/4885CDC25B 4531/4885 |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | ALDH1A1 2622/4885HPGD 4244/4885CDC25B 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.